|
⚲
|
| Ascenta Therapeutics Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001483471 |
| Sale | 2010-01-25 ($15.0 M Offered, $1.8 M Sold) |
| Fund | |
| Phone | 6104080301 |
| Address | 101 Lindenwood Drive, Suite 405 Malvern, 19355 |
| Source | [EDGAR] |
| Fund AUM and Sold ($k) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| Marc Lippman | |
| Andrew Senyei | |
| J Mel Sorensen | |
| Louis Bock | |
| Michael Powell | |
| Norman Selby | |
| Eckard Weber | |
| Joel Sussman |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
JE Fund I, a series of Unpopular VC, LP
✚
|
0.0 | |
|
JE Fund II, a series of Unpopular VC, LP
✚
|
0.0 | |
|
Jeifetz Martha V.
✚
|
0.0 | |
|
JEM Ventures Series 1
✚
|
0.0 | |
|
JEM Ventures Series 2
✚
|
0.0 | |
|
Jengu Therapeutics, Inc.
✚
|
0.0 | |
|
Jenkins David H
✚
|
0.0 | |
|
Jenkin Thomas M
✚
|
0.0 | |
|
Jennings Kevin
✚
|
0.0 | |
|
Jedar Capital Cohort 16, a Series of Assure Labs 2022, LLC
✚
|
0.0 |